Neurocrine Biosciences INC 10-Q quarterly reports

Neurocrine Biosciences reported a significant increase in net income and revenue for the first quarter of 2026, driven by robust sales of INGREZZA and CRENESSITY, alongside progress in its development pipeline and a major acquisition.

Neurocrine Biosciences reports significant revenue growth driven by INGREZZA and CRENESSITY sales, alongside multiple pipeline advancements, despite increased operating expenses and a Phase 3 clinical trial setback.

Neurocrine Biosciences announced increased net product sales for the first half of 2025, driven by INGREZZA and the recent launch of CRENESSITY, despite higher operating expenses and a Phase 3 study setback for valbenazine in schizophrenia.

Neurocrine Biosciences' Q1 2025 results show revenue growth driven by INGREZZA sales, offset by increased R&D expenses and fluctuations in equity investments.

Neurocrine Biosciences reports a strong third quarter with increased product sales and pipeline advancements, while also announcing a CEO transition and share repurchase program.

Neurocrine Biosciences reports a significant increase in net product sales, driven by INGREZZA, and progresses its clinical programs in neurology and psychiatry.

Neurocrine Biosciences' first quarter of 2024 saw a net income of $43.4 million, driven by increased INGREZZA sales and reduced research and development expenses.